News
Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback